+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa



In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa



Bmc Infectious Diseases 16(1): 444



Multidrug-resistant Pseudomonas aeruginosa has emerged as one of the most important healthcare-associated pathogens. Colistin is regarded as the last-resort antibiotic for multidrug-resistant Gram-negative bacteria, but is associated with high rates of acute kidney injury. The aim of this in vitro study is to search for an alternative treatment to colistin for multidrug-resistant P. aeruginosa infections. Multidrug and carbapenem-resistant P. aeruginosa isolates were collected between January 2009 and December 2012 at MacKay Memorial Hospital. Minimal inhibitory concentrations (MICs) were determined for various antibiotic combinations. Carbapenemase-producing genes including bla VIM, other β-lactamase genes and porin mutations were screened by PCR and sequencing. The efficacy of carbapenems (imipenem, meropenem, doripenem) with or without rifampicin was correlated with the type of porin mutation (frameshift mutation, premature stop codon mutation) in multidrug-resistant P. aeruginosa isolates without carbapenemase-producing genes. Of the 71 multidrug-resistant clinical P. aeruginosa isolates, only six harboured the bla VIM gene. Imipenem, meropenem and doripenem were significantly more effective (reduced fold-change of MICs) when combined with rifampicin in bla VIM-negative isolates, especially in isolates with porin frameshift mutation. Imipenem + rifampicin combination has a low MIC against multidrug-resistant P. aeruginosa, especially in isolates with porin frameshift mutation. The imipenem + rifampicin combination may provide an alternative treatment to colistin for multidrug -resistant P. aeruginosa infections, especially for patients with renal insufficiency.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058085546

Download citation: RISBibTeXText

PMID: 27553962

DOI: 10.1186/s12879-016-1785-7


Related references

Comparison of the in vitro activity of meropenem and doripenem against Pseudomonas aeruginosa and multidrug-resistant Enterobacteriaceae. Acta Clinica Belgica 65(6): 451, 2010

Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland. Polski Przeglad Chirurgiczny 84(9): 449-453, 2012

In Vitro Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii , Pseudomonas aeruginosa , and Klebsiella pneumoniae Isolates. Canadian Journal of Infectious Diseases and Medical Microbiology 2018: 1047670, 2018

Comparative antibacterial activities of meropenem , imipenem , ceftazidime , piperacillin/tazobactam , ciprofloxacin and tobramycin , singly and in combination against resistant and susceptible isolates of Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 35: 104, 1995

Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa. Journal of Antimicrobial ChemoTherapy 63(6): 1297-1299, 2009

Successful treatment of post-neurosurgical multidrug-resistant Pseudomonas aeruginosa meningo-encephalitis with combination therapy of colistin, rifampicin and doripenem. Journal of Antimicrobial ChemoTherapy 69(3): 857-859, 2014

In vitro combined effects of double antibacterial drugs against multidrug-resistant Pseudomonas aeruginosa isolates: comparison among combinations of colistin, arbekacin, aztreonam, rifampicin and piperacillin. Japanese Journal of Antibiotics 67(3): 167-174, 2014

In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates. Diagnostic Microbiology and Infectious Disease 71(3): 297-300, 2011

The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. International Journal of Antimicrobial Agents 20(5): 384-386, 2002

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant Pseudomonas aeruginosa Strains. Chemotherapy 49(6): 294-297, 2003

In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. ChemoTherapy 49(6): 294-297, 2003

In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 25(2): 181-182, 2005

Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Journal of Antimicrobial ChemoTherapy 66(9): 2022-2027, 2011

In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia. Journal of ChemoTherapy 3(3): 143-146, 1991

In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Journal of Antimicrobial ChemoTherapy 45(6): 899-901, 2000